Glycemic control in 
MetS
Among the 1274 patients, 766 met three or more criteria of the ATP III MetS definition and were assigned to the MetS subgroup, and the other 508 patients were assigned to the non‐MetS subgroup. At baseline, there were 111, 265, 249, and 141 patients in the placebo, chiglitazar 32 mg, chiglitazar 48 mg, and sitagliptin 100 mg arms of the MetS subgroup. After 24 weeks of treatment, the numbers of patients reverting to non‐MetS were 20 (18%), 98 (37%), 100 (40%), and 53 (38%) in the respective arms. At week 24, the HbA1c levels in the chiglitazar 48 mg and chiglitazar 32 mg arms decreased from baseline by 1.68% and 1.44%, respectively. A statistically significant distinction was observed when comparing the LSM difference of chiglitazar 48 mg with those of sitagliptin 100 mg, yielding a Glycemic control in MetS and non‐MetS patients. *